Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Operating Leases: 2020-2025

Historic Operating Leases for Lyell Immunopharma (LYEL) over the last 5 years, with Sep 2025 value amounting to $53.1 million.

  • Lyell Immunopharma's Operating Leases fell 9.39% to $53.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.1 million, marking a year-over-year decrease of 9.39%. This contributed to the annual value of $51.0 million for FY2024, which is 10.37% down from last year.
  • As of Q3 2025, Lyell Immunopharma's Operating Leases stood at $53.1 million, which was down 3.69% from $55.1 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Operating Leases peaked at $68.8 million during Q1 2022, and registered a low of $51.0 million during Q4 2024.
  • For the 3-year period, Lyell Immunopharma's Operating Leases averaged around $59.2 million, with its median value being $58.6 million (2024).
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 30.80% in 2021, then decreased by 10.37% in 2024.
  • Quarterly analysis of 5 years shows Lyell Immunopharma's Operating Leases stood at $66.7 million in 2021, then dropped by 5.22% to $63.2 million in 2022, then dropped by 9.93% to $56.9 million in 2023, then decreased by 10.37% to $51.0 million in 2024, then dropped by 9.39% to $53.1 million in 2025.
  • Its Operating Leases was $53.1 million in Q3 2025, compared to $55.1 million in Q2 2025 and $57.1 million in Q1 2025.